

Erratum to: Pharmacokinetic Evaluations of the Co-Administrations of Vandetanib and Metformin, Digoxin, Midazolam, Omeprazole or Ranitidine

Susanne Johansson · Jessica Read · Stuart Oliver ·
Mark Steinberg · Yan Li · Eleanor Lisbon ·
David Mathews · Philip T. Leese · Paul Martin

Published online: 26 September 2014
© Springer International Publishing Switzerland 2014

Erratum to: Clin Pharmacokinet (2014) 53:837–847
DOI 10.1007/s40262-014-0161-2

Page 837; column 2, para 4: The first key point, which previously read:

Vandetanib may lead to greater exposure to octamer transcription factor-2 substrates or P-glycoprotein substrates when co-administered.

Should read:

Vandetanib may lead to greater exposure to organic cation transporter 2 substrates or P-glycoprotein substrates when co-administered.

The online version of the original article can be found under doi:[10.1007/s40262-014-0161-2](https://doi.org/10.1007/s40262-014-0161-2).

S. Johansson (✉)
AstraZeneca R&D Mölndal, Quantitative Clinical
Pharmacology, SE-431 83 Mölndal, Sweden
e-mail: susanne.a.johansson@astrazeneca.com

J. Read
PRA International, Reading, UK

S. Oliver · P. Martin
AstraZeneca, Alderley Park, Macclesfield, UK

M. Steinberg · Y. Li
AstraZeneca, Wilmington, DE, USA

E. Lisbon · D. Mathews · P. T. Leese
Quintiles Phase I Services, Overland Park, KS, USA